Patents by Inventor Matthew Davison
Matthew Davison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399388Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: December 9, 2022Publication date: December 14, 2023Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20230235088Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: August 10, 2022Publication date: July 27, 2023Inventors: Ercole RAO, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Patent number: 11453727Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: July 28, 2020Date of Patent: September 27, 2022Assignee: SANOFIInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Publication number: 20210148441Abstract: A machine for the conversion of segmented linear force into rational force around a fulcrum at a mechanical advantage to an included or attached drive mechanism. A body consisting of pivot arms, drive mechanism, primary shaft, and bearings. With the pivot arms bolted around standard bearings that are attached to a primary stationary primary shaft a mechanical advantage of a pulley is created to an included or attached drive mechanism. The segmented linear force in this application includes, but is not limited to, an electromagnetic force or compressed air or manual labor. A machine that converts segmented linear force at a mechanical advantage directly to an incorporated or attached drive mechanism such as a gear, pulley, or drive secondary shaft.Type: ApplicationFiled: November 18, 2019Publication date: May 20, 2021Inventor: Greg Matthew Davison
-
Publication number: 20210047437Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: July 28, 2020Publication date: February 18, 2021Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Patent number: 10759871Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: July 10, 2017Date of Patent: September 1, 2020Assignee: SANOFIInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Publication number: 20200115441Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: September 24, 2019Publication date: April 16, 2020Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 10465002Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: December 18, 2017Date of Patent: November 5, 2019Assignee: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20180222967Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: December 18, 2017Publication date: August 9, 2018Inventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20180030156Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: July 10, 2017Publication date: February 1, 2018Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
-
Patent number: 9879079Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: May 25, 2016Date of Patent: January 30, 2018Assignee: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 9738728Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: March 11, 2013Date of Patent: August 22, 2017Assignee: SanofiInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Patent number: 9732162Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: March 15, 2013Date of Patent: August 15, 2017Assignee: SanofiInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Patent number: 9680361Abstract: An electric motor apparatus that includes a disk with an increased mechanical advantage to the attached axle, with donut-shaped permanent magnets, windings, a fulcrum (A.K.A. axle), bearings, a commutator, and a single bearing conductor that replaces the brushes. The center axis consists of the windings and spools with the axis of the windings placed coradial in orbit around the fulcrum of a disk. The donut-shaped permanent magnets are cut with a slot to allow passage of the disk, spools, and windings. When windings of magnet wire are inserted with windings around the spools such that the center points of the faces of the spools are concentric to the same radius of the disk and pass through the center of a donut-shaped permanent magnet, and the windings are electrified with the correct polarity, the windings are repulsed magnetically in the direction of rotation of the orbit around the fulcrum (A.K.A. axle) causing the disk and axle to rotate.Type: GrantFiled: September 15, 2013Date of Patent: June 13, 2017Inventor: Greg Matthew Davison
-
Publication number: 20160368976Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kanidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kanidin activity or detect Kallidin or des-Arg10-Kanidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: May 25, 2016Publication date: December 22, 2016Applicant: SanofiInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 9376494Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: GrantFiled: March 15, 2013Date of Patent: June 28, 2016Assignee: SanofiInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritsker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20160170931Abstract: A console server that can be configured to include USB and RJ-45 serial ports is disclosed. The USB serial ports are provided by a USB serial card, and are configured to provide communications with a device having a USB serial port, but lacking an RJ-45 serial port.Type: ApplicationFiled: December 11, 2015Publication date: June 16, 2016Inventors: Van Quach, Matthew Davison
-
Publication number: 20150076971Abstract: An electric motor apparatus that includes a disk with an increased mechanical advantage to the axle, donut-shaped permanent magnets, windings, a fulcrum (A.K.A. axle), bearings, a commutator, and a single bearing conductor that replaces the brushes. The windings with the axis placed parallel to the orbit around the fulcrum on a disk. The donut-shaped permanent magnets are cut with a slot to allow passage of the disk, spools, and windings. When windings of magnet wire are inserted with the axis parallel to the orbit around an axle inside the center of a donut-shaped permanent magnet, and the windings are electrified with the correct polarity, the windings are repulsed magnetically in the direction of rotation of the orbit around the fulcrum causing the disk and axle to rotate.Type: ApplicationFiled: September 15, 2013Publication date: March 19, 2015Inventor: Greg Matthew Davison
-
Publication number: 20150050270Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: March 15, 2013Publication date: February 19, 2015Applicant: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritzker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Publication number: 20140023649Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: ApplicationFiled: March 15, 2013Publication date: January 23, 2014Applicant: SANOFIInventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON